About ZYDELIG®

What sets ZYDELIG apart?

  • It's an oral medication: ZYDELIG is an oral medication used to treat relapsed follicular lymphoma, relapsed CLL, or relapsed SLL
  • It works differently: ZYDELIG was approved in 2014 and works by blocking PI3K delta, a protein that contributes to follicular lymphoma, CLL, and SLL growth2,3

ZYDELIG for relapsed follicular lymphoma

ZYDELIG is approved for use in follicular B-cell non-Hodgkin lymphoma when the disease worsens after treatment with at least 2 prior medicines. ZYDELIG was approved based on response rates. Data are not yet available to show if ZYDELIG improves symptoms or survival.

ZYDELIG for relapsed CLL

ZYDELIG is approved for use in combination with Rituxan® (rituximab) when CLL comes back after prior cancer treatment and when Rituxan treatment alone may be used due to other health problems.

ZYDELIG for relapsed SLL

ZYDELIG is approved for use in small lymphocytic lymphoma (SLL) when the disease worsens after treatment with at least 2 prior medicines. ZYDELIG was approved based on response rates. Data are not yet available to show if ZYDELIG improves symptoms or survival.

ZYDELIG should not be used as the first medicine to treat people who have been diagnosed with CLL, follicular lymphoma, or SLL, and should not be used in combination with bendamustine and/or Rituxan to treat people with follicular lymphoma.

References:

  1. ZYDELIG® (idelalisib) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; rev January 2018.
  2. Robak P, Robak T. The emerging role of ibrutinib and idelalisib in the treatment of chronic lymphocytic leukemia. J Hematol Transfus. 2013;1(1):1001.
  3. NCI Dictionary of Cancer Terms. National Cancer Institute website. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed July 21, 2017.